LeonaBio, Inc.
LONA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001620463
No open-market purchases or sales by LeonaBio, Inc. insiders were filed in the last 90 days; 44 institutions reported holding it in 13F filings for Q2 2026, worth $70.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 44
- 13F valueReported value at the end of Q2 2026
- $70.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LONA, Q2 2026
No superinvestor reported holding LONA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by LeonaBio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Renninger RobertCHIEF FINANCIAL OFFICER | SSale | −906 | $5.37 | −$4.87K | −5.4%15.9K after | |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Worthington MarkGENERAL COUNSEL and CCO | SSale | −1.33K | $5.37 | −$7.13K | −6.7%18.4K after | |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Church KevinCHIEF SCIENTIFIC OFFICER | SSale | −1.36K | $5.37 | −$7.30K | −5.1%25.2K after | |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | San Martin JavierCHIEF MEDICAL OFFICER | SSale | −1.72K | $5.37 | −$9.24K | −9.8%15.9K after | |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Litton Mark JamesPRESIDENT and CEO | SSale | −5.16K | $5.37 | −$27.7K | −8.2%57.9K after | |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Renninger RobertChief Financial Officer | SSale | −297 | $6.88 | −$2.04K | −2.3%12.9K after | |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Worthington MarkGeneral Counsel and CCO | SSale | −876 | $6.88 | −$6.03K | −5.9%14.0K after | |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Church KevinCHIEF SCIENTIFIC OFFICER | SSale | −876 | $6.88 | −$6.03K | −4.1%20.7K after | |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | San Martin JavierCHIEF MEDICAL OFFICER | SSale | −1.64K | $6.88 | −$11.3K | −13.9%10.2K after | |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Litton Mark JamesPresident and CEO | SSale | −2.59K | $6.88 | −$17.8K | −6.0%40.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in LeonaBio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 1,859,322 | $17.1M | 0.27% | 00.0% | Unchanged |
| Kalehua Capital Management LLC | 787,402 | $7.24M | 2.31% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 777,100 | $7.14M | 0.34% | +49,619+6.8% | Added |
| Acorn Capital Advisors, LLC | 634,539 | $5.83M | 1.59% | 00.0% | Unchanged |
| NEA Management Company, LLC | 464,398 | $4.27M | 0.27% | 00.0% | Unchanged |
| Commodore Capital LP | 464,398 | $4.27M | 0.25% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 464,398 | $4.27M | 0.10% | 00.0% | Unchanged |
| Spruce Street Capital LP | 393,701 | $3.62M | 0.71% | 00.0% | Unchanged |
| Blackstone Group Inc. | 324,638 | $2.98M | 0.01% | +324,638 | New |
| Adage Capital Partners GP, L.L.C. | 300,000 | $2.76M | 0.00% | +300,000 | New |